SUPPLEMENTARY APPENDIX

Dexamethasone promotes durable factor VIII-specific tolerance in hemophilia A mice via thymic mechanisms

Maria T. Georgescu,[1] Paul C. Moorehead,[2,3] Alice S. van Velzen,[4] Kate Nesbitt,[1] Birgit M. Reipert,[5] Katharina N. Steinitz,[5] Maria Schuster,[5] Christine Hough[1] and David Lillicrap[1]

[1]Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada; [2]Janeway Children's Health and Rehabilitation Centre, St. John's, NL, Canada; [3]Faculty of Medicine, Memorial University, St. John's, NL, Canada; [4]Department of Pediatric Hematology, Immunology and Infectious Diseases, Emma Children's Hospital, Amsterdam, the Netherlands and [5]Baxalta Innovations GmbH, Vienna, Austria

 doi:10.3324/haematol.2018.189852

Received: January 30, 2018.

Accepted: April 19, 2018.

Pre-published: April 19, 2018.

Correspondence: david.lillicrap@queensu.ca

Supplementary Material



Figure S1. Administration of Dex during initial FVIII exposure does not impair the immune response to VWF. Anti-VWF IgG incidence at week 22, following exposure to VWF (Week 18-21) in mice initially treated with FVIII or FVIII+Dex and with no evidence of anti-FVIII IgG at week 4.

Table S1. Genes down-regulated following FVIII+Dex treatment.

	Transcript Count Ratio	
Gene Name	**FVIII+Dex vs FVIII**	**Dex vs HBSS**
Ccr4	-5.82	-14.45
Rag1	-4.18	-16.00
Cd69	-3.51	-4.40
Ccr9	-3.46	-9.90
Slamf1	-3.20	-6.50
Cd8b1	-3.18	-7.77
Cd40lg	-2.99	-2.56
Cxcl1	-2.90	-2.37
Rag2	-2.84	-9.21
Rorc	-2.78	-5.65
Cd8a	-2.67	-7.74
Cd4	-2.66	-5.06
Il9	-2.64	-2.26
Il12b	-2.60	-2.49
Bcl6	-2.59	-3.30
Il27	-2.54	-3.06
Mr1	-2.48	-3.26
Sh2d1a	-2.39	-6.68
Il13	-2.23	-2.38
Ccl22	-2.22	-2.51
Il16	-2.22	-3.05
Socs1	-2.20	-4.55
Card9	-2.12	-3.32
Cxcr4	-2.12	-3.98
Tcf7	-2.12	-5.16
Lck	-2.06	-4.47
Icam2	-2.02	-3.09

Table S2. Genes up-regulated following FVIIII+Dex treatment.

	Transcript Count Ratio	
Gene Name	**FVIII+Dex vs FVIII**	**Dex vs HBSS**
Cd36	7.20	19.89
Cfd	7.17	10.08
Mme	6.10	22.78
Pparg	5.80	20.07
Tlr5	5.53	20.38
H2-Q10	5.08	25.14
C7	4.60	10.55
Il18rap	3.89	3.10
Itga2b	3.75	58.09
C4a	3.71	12.35
Cd209g	3.63	25.37
Il22ra2	3.20	53.55
Ppbp	3.16	11.22
Pdgfrb	2.72	3.28
Tal1	2.41	3.33
Il33	2.27	5.11
Fn1	2.26	3.90
Gzmb	2.21	3.17
Marco	2.19	175.11
Cfh	2.18	4.25
Cxcl13	2.16	19.57
Cdh5	2.15	6.77
Cebpb	2.14	5.60
Cd14	2.08	3.84
Bst1	2.02	2.11
Vtn	2.02	5.02
Serping1	2.01	5.53



Figure S2. Intense FVIII exposure does not alter the thymic or splenic mRNA transcript profile of E16KO mice. A. Thymic and **B.** Splenic mRNA transcript counts three days after treatment with FVIII (6 IU IV) versus mRNA transcript counts three days after treatment with HBSS alone (250 µl IV, 100 µl IP). Each point corresponds with the average mRNA transcript count of 3 different tissue samples. n=3 for each condition.